1. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
- Author
-
Patti G, Fossati C, Manzoli A, D'Ambrosio A, Abbate A, Montesanti R, and Di Sciascio G
- Subjects
- Abciximab, Acetates therapeutic use, Angioplasty, Balloon, Coronary, Antibodies, Monoclonal therapeutic use, Diabetes Complications, Eptifibatide, Fibrinolytic Agents adverse effects, Humans, Immunoglobulin Fab Fragments therapeutic use, Multicenter Studies as Topic, Myocardial Ischemia blood, Myocardial Ischemia complications, Myocardial Ischemia mortality, Peptides therapeutic use, Platelet Aggregation Inhibitors adverse effects, Randomized Controlled Trials as Topic, Stents, Survival Analysis, Syndrome, Tirofiban, Treatment Outcome, Troponin blood, Tyrosine therapeutic use, Fibrinolytic Agents therapeutic use, Myocardial Ischemia drug therapy, Platelet Aggregation Inhibitors therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, Platelet Glycoprotein GPIIb-IIIa Complex metabolism, Tyrosine analogs & derivatives
- Abstract
Glycoprotein IIb-IIIa receptor inhibitors are the newest anti-platelets drugs currently used in patients with coronary artery disease. We examined mechanisms of their action and different pharmacokinetic and pharmacodynamic characteristics of the four glycoprotein IIb-IIIa antagonists evaluated in randomized, controlled and multicenter trials. We reviewed results of these trials in the settings of percutaneous revascularizations procedures or unstable coronary syndromes. Platelet glycoprotein IIb-IIIa receptor inhibitors reduced incidence of cardiac death and myocardial infarction during the short- and midterm, and benefit was greater in: a) patients undergoing coronary angioplasty with or without stent implantation, particularly in the presence of unstable angina, diabetes or complex and diffuse coronary artery disease; b) as a direct therapy of unstable coronary syndromes, particularly in patients with refractory angina, diabetes and elevated Troponin; more recently they have been used as adjuvant therapy in acute myocardial infarction. Infusion of these drugs was not associated with higher rates of major bleedings.
- Published
- 2000